Robert C Wolf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4961359/publications.pdf

Version: 2024-02-01

197 papers

6,828 citations

76031 42 h-index 68 g-index

222 all docs 222 docs citations

times ranked

222

9146 citing authors

#	Article	IF	CITATIONS
1	Structural alterations of amygdala and hypothalamus contribute to catatonia. Schizophrenia Research, 2024, 263, 122-130.	1.1	8
2	The origins of catatonia – Systematic review of historical texts between 1800 and 1900. Schizophrenia Research, 2024, 263, 6-17.	1.1	10
3	Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. Journal of Oncology Pharmacy Practice, 2022, 28, 387-394.	0.5	O
4	Multimodal MRI data fusion reveals distinct structural, functional and neurochemical correlates of heavy cannabis use. Addiction Biology, 2022, 27, e13113.	1.4	14
5	Characterizing the sensorimotor domain in schizophrenia spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1097-1108.	1.8	12
6	The polysemous concepts of psychomotricity and catatonia: A European multi-consensus perspective. European Neuropsychopharmacology, 2022, 56, 60-73.	0.3	19
7	Different faces of catatonia and how to approach them. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1385-1387.	1.8	2
8	Cortical folding complexity is distinctively altered in schizophrenia and bipolar disorder. Schizophrenia Research, 2022, 241, 92-93.	1.1	5
9	Time After Time: Electroconvulsive Therapy Modulates the Brain's Functional Network Connectivity Dynamics. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 243-245.	1.1	O
10	Neural Correlates of the Risk for Schizophrenia and Bipolar Disorder: A Meta-analysis of Structural and Functional Neuroimaging Studies. Biological Psychiatry, 2022, 92, 375-384.	0.7	20
11	Cortical surface variation in individuals with excessive smartphone use. Developmental Neurobiology, 2022, 82, 277-287.	1.5	3
12	Multiparametric assessment of sensorimotor abnormalities in vulnerable populations: A window of opportunity. Neuroscience and Biobehavioral Reviews, 2022, 137, 104658.	2.9	0
13	Catatonia: looking back and moving forward. Brain, 2022, 145, 2939-2942.	3.7	16
14	GABAB receptor, clozapine, and catatonia—a complex triad. Molecular Psychiatry, 2021, 26, 2683-2684.	4.1	16
15	Cognition and Cortical Thickness in Heavy Cannabis Users. European Addiction Research, 2021, 27, 115-122.	1.3	11
16	Why is there symptom coupling of psychological and motor changes in psychomotor mechanisms? Insights from the brain's topography. Molecular Psychiatry, 2021, 26, 3669-3671.	4.1	13
17	All roads lead to the motor cortex: psychomotor mechanisms and their biochemical modulation in psychiatric disorders. Molecular Psychiatry, 2021, 26, 92-102.	4.1	96
18	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 274-277.	1.3	1

#	Article	IF	CITATIONS
19	Neurological Soft Signs Predict Auditory Verbal Hallucinations in Patients With Schizophrenia. Schizophrenia Bulletin, 2021, 47, 433-443.	2.3	18
20	Vasogenic Brain Edema During Maintenance Hemodialysis. Clinical Neuroradiology, 2021, 31, 217-224.	1.0	9
21	Neural Responses of Benefiting From the Prosocial Exchange: The Effect of Helping Behavior. Frontiers in Psychology, 2021, 12, 606858.	1.1	9
22	Right parietotemporal activity predicts sense of agency under uncertain delays of sensory outcomes. Journal of Neurophysiology, 2021, 125, 903-914.	0.9	1
23	Structural alterations in brainstem, basal ganglia and thalamus associated with parkinsonism in schizophrenia spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1455-1464.	1.8	6
24	Antipsychotic-induced catatonia and neuroleptic malignant syndrome: the dark side of the moon. Molecular Psychiatry, 2021, 26, 6112-6114.	4.1	11
25	Structural correlates of sensorimotor dysfunction in heavy cannabis users. Addiction Biology, 2021, 26, e13032.	1.4	6
26	A neurodevelopmental signature of parkinsonism in schizophrenia. Schizophrenia Research, 2021, 231, 54-60.	1.1	11
27	Sensorimotor Neuroscience in Mental Disorders: Progress, Perspectives and Challenges. Schizophrenia Bulletin, 2021, 47, 880-882.	2.3	15
28	Intrinsic neural network dynamics in catatonia. Human Brain Mapping, 2021, 42, 6087-6098.	1.9	22
29	Cortical morphology and illness insight in patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2021, , 1.	1.8	4
30	White matter microstructure alterations in cortico-striatal networks are associated with parkinsonism in schizophrenia spectrum disorders. European Neuropsychopharmacology, 2021, 50, 64-74.	0.3	6
31	Early life maltreatment affects intrinsic neural function in mothers. Journal of Psychiatric Research, 2021, 143, 176-182.	1.5	3
32	Progress in sensorimotor neuroscience of schizophrenia spectrum disorders: Lessons learned and future directions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110370.	2.5	14
33	Exploring joint patterns of brain structure and function in inflammatory bowel diseases using multimodal data fusion. Neurogastroenterology and Motility, 2021, 33, e14078.	1.6	23
34	Going Back to Kahlbaum's Psychomotor (and GABAergic) Origins: Is Catatonia More Than Just a Motor and Dopaminergic Syndrome?. Schizophrenia Bulletin, 2020, 46, 272-285.	2.3	39
35	Multimodal Magnetic Resonance Imaging Data Fusion Reveals Distinct Patterns of Abnormal Brain Structure and Function in Catatonia. Schizophrenia Bulletin, 2020, 46, 202-210.	2.3	58
36	Cognitive remediation therapy modulates intrinsic neural activity in patients with major depression. Psychological Medicine, 2020, 50, 2335-2345.	2.7	10

#	Article	IF	CITATIONS
37	Exploring cortical predictors of clinical response to electroconvulsive therapy in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 253-261.	1.8	15
38	Motor domain in psychotic disorders: the rebirth of a concept. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 399-400.	1.8	3
39	Altered resting-state dynamic functional brain networks in major depressive disorder: Findings from the REST-meta-MDD consortium. Neurolmage: Clinical, 2020, 26, 102163.	1.4	76
40	Electroconvulsive therapy modulates grey matter increase in a hub of an affect processing network. Neurolmage: Clinical, 2020, 25, 102114.	1.4	17
41	Predictors of cognitive remediation therapy improvement in (partially) remitted unipolar depression. Journal of Affective Disorders, 2020, 264, 40-49.	2.0	11
42	Neurological soft signs in schizophrenia spectrum disorders are not confounded by current antipsychotic dosage. European Neuropsychopharmacology, 2020, 31, 47-57.	0.3	5
43	Brainstem alterations contribute to catatonia in schizophrenia spectrum disorders. Schizophrenia Research, 2020, 224, 82-87.	1.1	9
44	Cognitive remediation therapy for partially remitted unipolar depression: A single-blind randomized controlled trial. Journal of Affective Disorders, 2020, 276, 316-326.	2.0	25
45	Movement disorder and sensorimotor abnormalities in schizophrenia and other psychoses - European consensus on assessment and perspectives. European Neuropsychopharmacology, 2020, 38, 25-39.	0.3	37
46	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	1.3	8
47	Multiparametric mapping of white matter microstructure in catatonia. Neuropsychopharmacology, 2020, 45, 1750-1757.	2.8	44
48	Functional Decoupling of Language and Self-Reference Networks in Patients with Persistent Auditory Verbal Hallucinations. Neuropsychobiology, 2020, 79, 345-351.	0.9	6
49	A Neural Signature of Parkinsonism in Patients With Schizophrenia Spectrum Disorders: A Multimodal MRI Study Using Parallel ICA. Schizophrenia Bulletin, 2020, 46, 999-1008.	2.3	20
50	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leukemia and Lymphoma, 2020, 61, 1592-1600.	0.6	17
51	Aberrant Gray Matter Volume and Cortical Surface in Paranoid-Type Delusional Disorder. Neuropsychobiology, 2020, 79, 335-344.	0.9	10
52	Moving forward: distinct sensorimotor abnormalities predict clinical outcome after 6 months in patients with schizophrenia. European Neuropsychopharmacology, 2020, 36, 72-82.	0.3	13
53	Abnormal Cerebellar Volume in Patients with Remitted Major Depression with Persistent Cognitive Deficits. Cerebellum, 2020, 19, 762-770.	1.4	15
54	Oxytocin modulates intrinsic neural activity in patients with chronic low back pain. European Journal of Pain, 2020, 24, 945-955.	1.4	16

#	Article	IF	CITATIONS
55	Structural and functional correlates of smartphone addiction. Addictive Behaviors, 2020, 105, 106334.	1.7	110
56	Abnormal cerebellar volume in somatic vs. non-somatic delusional disorders. Cerebellum and Ataxias, 2020, 7, 2.	1.9	4
57	Neural correlates of cue reactivity in individuals with smartphone addiction. Addictive Behaviors, 2020, 108, 106422.	1.7	30
58	Patterns of coâ€altered brain structure and function underlying neurological soft signs in schizophrenia spectrum disorders. Human Brain Mapping, 2019, 40, 5029-5041.	1.9	28
59	Cortical neurodevelopment in pre-manifest Huntington's disease. Neurolmage: Clinical, 2019, 23, 101913.	1.4	19
60	Transdiagnostic modulation of brain networks by electroconvulsive therapy in schizophrenia and major depression. European Neuropsychopharmacology, 2019, 29, 925-935.	0.3	18
61	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	2.0	36
62	Functional neuroimaging in treatment resistant schizophrenia: A systematic review. Neuroscience and Biobehavioral Reviews, 2019, 104, 178-190.	2.9	21
63	GABA and Negative Affect—Catatonia as Model of RDoC-Based Investigation in Psychiatry. Schizophrenia Bulletin, 2019, 45, 1168-1169.	2.3	12
64	Embarking on antidepressant response prediction using brain perfusion estimation. EClinicalMedicine, 2019, 10, 4-5.	3.2	1
65	Differential contributions of brainstem structures to neurological soft signs in first- and multiple-episode schizophrenia spectrum disorders. Schizophrenia Research, 2019, 210, 101-106.	1.1	15
66	Oxytocin Effects on Pain Perception and Pain Anticipation. Journal of Pain, 2019, 20, 1187-1198.	0.7	17
67	A search for cortical correlates of trait impulsivity in Parkinson´s disease. Behavioural Brain Research, 2019, 369, 111911.	1.2	14
68	Structure/function interrelationships in patients with schizophrenia who have persistent auditory verbal hallucinations: A multimodal MRI study using parallel ICA. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 93, 114-121.	2.5	26
69	Aberrant brain structural largeâ€scale connectome in Crohn's disease. Neurogastroenterology and Motility, 2019, 31, e13593.	1.6	17
70	Mindfulness-based therapy modulates default-mode network connectivity in patients with opioid dependence. European Neuropsychopharmacology, 2019, 29, 662-671.	0.3	16
71	Cortical Contributions to Distinct Symptom Dimensions of Catatonia. Schizophrenia Bulletin, 2019, 45, 1184-1194.	2.3	48
72	Electroconvulsive therapy induced gray matter increase is not necessarily correlated with clinical data in depressed patients. Brain Stimulation, 2019, 12, 335-343.	0.7	49

#	Article	IF	CITATIONS
73	Neural signatures of the risk for bipolar disorder: A metaâ€enalysis of structural and functional neuroimaging studies. Bipolar Disorders, 2019, 21, 215-227.	1.1	73
74	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1077-1081.	1.3	7
75	Aberrant cortical neurodevelopment in major depressive disorder. Journal of Affective Disorders, 2019, 243, 340-347.	2.0	42
76	The relevance of hippocampal subfield integrity and clock drawing test performance for the diagnosis of Alzheimer's disease and mild cognitive impairment. World Journal of Biological Psychiatry, 2019, 20, 197-208.	1.3	9
77	Motor dysfunction as research domain in the period preceding manifest schizophrenia: A systematic review. Neuroscience and Biobehavioral Reviews, 2018, 87, 87-105.	2.9	52
78	Mindfulness-based interventions modulate structural network strength in patients with opioid dependence. Addictive Behaviors, 2018, 82, 50-56.	1.7	12
79	Commentary on "Motor system dysfunction in the schizophrenia diathesis: Neural systems to neurotransmitters― European Psychiatry, 2018, 48, 49-50.	0.1	4
80	Cortical folding abnormalities in patients with schizophrenia who have persistent auditory verbal hallucinations. European Neuropsychopharmacology, 2018, 28, 297-306.	0.3	18
81	Motor dysfunction as an intermediate phenotype across schizophrenia and other psychotic disorders: Progress and perspectives. Schizophrenia Research, 2018, 200, 26-34.	1.1	26
82	Aberrant resting-state cerebellar blood flow in major depression. Journal of Affective Disorders, 2018, 226, 227-231.	2.0	18
83	Regional gray matter volume and structural network strength in somatic vs. non-somatic delusional disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 82, 115-122.	2.5	12
84	Anterior cingulate volume predicts response to psychotherapy and functional connectivity with the inferior parietal cortex in major depressive disorder. European Neuropsychopharmacology, 2018, 28, 138-148.	0.3	47
85	Intrinsic Network Connectivity Patterns Underlying Specific Dimensions of Impulsiveness in Healthy Young Adults. Brain Topography, 2018, 31, 477-487.	0.8	7
86	Cerebellar Contributions to Major Depression. Frontiers in Psychiatry, 2018, 9, 634.	1.3	81
87	O19. Electroconvulsive Therapy Modulates Gray Matter Increase in a Hub of an Affect Processing Network. Biological Psychiatry, 2018, 83, S115-S116.	0.7	0
88	Motor dysfunction as research domain across bipolar, obsessive-compulsive and neurodevelopmental disorders. Neuroscience and Biobehavioral Reviews, 2018, 95, 315-335.	2.9	41
89	Differential contributions of cortical thickness and surface area to trait impulsivity in healthy young adults. Behavioural Brain Research, 2018, 350, 65-71.	1.2	15
90	Common and distinct patterns of abnormal cortical gyrification in major depression and borderline personality disorder. European Neuropsychopharmacology, 2018, 28, 1115-1125.	0.3	30

#	Article	IF	Citations
91	Neuromodulation in response to electroconvulsive therapy in schizophrenia and major depression. Brain Stimulation, 2017, 10, 637-644.	0.7	45
92	Hippocampal formation alterations differently contribute to autobiographic memory deficits in mild cognitive impairment and Alzheimer's disease. Hippocampus, 2017, 27, 702-715.	0.9	18
93	Cortical signature of clock drawing performance in Alzheimer's disease and mild cognitive impairment. Journal of Psychiatric Research, 2017, 90, 133-142.	1.5	11
94	White matter microstructure variations contribute to neurological soft signs in healthy adults. Human Brain Mapping, 2017, 38, 3552-3565.	1.9	16
95	Cortical features of distinct developmental trajectories in patients with delusional infestation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 72-79.	2.5	24
96	Intact sensory-motor network structure and function in far from onset premanifest Huntington's disease. Scientific Reports, 2017, 7, 43841.	1.6	11
97	Intrinsic neural network dysfunction in quiescent Crohn's Disease. Scientific Reports, 2017, 7, 11579.	1.6	41
98	Cerebellar Contributions to Persistent Auditory Verbal Hallucinations in Patients with Schizophrenia. Cerebellum, 2017, 16, 964-972.	1.4	34
99	Cortical folding patterns are associated with impulsivity in healthy young adults. Brain Imaging and Behavior, 2017, 11, 1592-1603.	1.1	20
100	Cerebellar volume change in response to electroconvulsive therapy in patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 73, 31-35.	2.5	37
101	Reacknowledging a "motor dimension―will lead to biologically reliable phenotypes and innovative treatment strategies in mental disorders. European Neuropsychopharmacology, 2016, 26, 1253-1254.	0.3	2
102	Mapping the brain correlates of borderline personality disorder: A functional neuroimaging meta-analysis of resting state studies. Journal of Affective Disorders, 2016, 204, 262-269.	2.0	49
103	Structural network changes in patients with major depression and schizophrenia treated with electroconvulsive therapy. European Neuropsychopharmacology, 2016, 26, 1465-1474.	0.3	38
104	Abnormal cerebellar volume in acute and remitted major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 97-102.	2.5	36
105	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biology of Blood and Marrow Transplantation, 2016, 22, 1431-1439.	2.0	26
106	Multiparametric mapping of neurological soft signs in healthy adults. Brain Structure and Function, 2016, 221, 1209-1221.	1.2	28
107	Motor network structure and function are associated with motor performance in Huntington's disease. Journal of Neurology, 2016, 263, 539-549.	1.8	30
108	Neuroanatomical Markers of Neurological Soft Signs in Recent-Onset Schizophrenia and Asperger-Syndrome. Brain Topography, 2016, 29, 382-394.	0.8	16

#	Article	IF	CITATIONS
109	The Incidence and Severity of Oral Mucositis among AllogeneicÂHematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of Blood and Marrow Transplantation, 2016, 22, 605-616.	2.0	103
110	Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. Biology of Blood and Marrow Transplantation, 2016, 22, 579-583.	2.0	19
111	Common and distinct structural network abnormalities in major depressive disorder and borderline personality disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 65, 127-133.	2.5	23
112	Cerebellar contributions to neurological soft signs in healthy young adults. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 35-41.	1.8	17
113	Altered Markers of Brain Development in Crohn's Disease with Extraintestinal Manifestations – A Pilot Study. PLoS ONE, 2016, 11, e0163202.	1.1	26
114	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 4593-4593.	0.6	0
115	Neural Compensation in Huntington's Disease: Teaching Mental Disorders New Tricks?. EBioMedicine, 2015, 2, 1288-1289.	2.7	2
116	Noninvasive brain stimulation for the treatment of auditory verbal hallucinations in schizophrenia: methods, effects and challenges. Frontiers in Systems Neuroscience, 2015, 9, 131.	1.2	21
117	Local brain gyrification as a marker of neurological soft signs in schizophrenia. Behavioural Brain Research, 2015, 292, 19-25.	1.2	40
118	Reward System Dysfunction as a Neural Substrate of Symptom Expression Across the General Population and Patients With Schizophrenia. Schizophrenia Bulletin, 2015, 41, 1370-1378.	2.3	57
119	Motor dysfunction within the schizophrenia-spectrum: A dimensional step towards an underappreciated domain. Schizophrenia Research, 2015, 169, 217-233.	1.1	88
120	Novel gene variations in early-onset frontotemporal dementia with positive family history of neural ceroid lipofuscinosis-1. Neurology: Clinical Practice, 2015, 5, 484-487.	0.8	3
121	Neurological soft signs in recent-onset schizophrenia: Focus on the cerebellum. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 60, 18-25.	2.5	39
122	Specificity of abnormal brain volume in major depressive disorder: A comparison with borderline personality disorder. Journal of Affective Disorders, 2015, 174, 650-657.	2.0	26
123	Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease. Journal of Neurology, 2015, 262, 859-869.	1.8	39
124	Neural network activity and neurological soft signs in healthy adults. Behavioural Brain Research, 2015, 278, 514-519.	1.2	32
125	Motor Abnormalities and Basal Ganglia in Schizophrenia: Evidence from Structural Magnetic Resonance Imaging. Brain Topography, 2015, 28, 135-152.	0.8	28
126	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. Blood, 2015, 126, 736-736.	0.6	2

#	Article	IF	CITATIONS
127	Baseline brain perfusion and brain structure in patients with major depression: a multimodal magnetic resonance imaging study. Journal of Psychiatry and Neuroscience, 2015, 40, 412-421.	1.4	57
128	Development of an Online Patient Decision Aid for Previously Treated Mantle Cell Lymphoma. Blood, 2015, 126, 5634-5634.	0.6	1
129	Revisiting default mode network function in major depression: evidence for disrupted subsystem connectivity. Psychological Medicine, 2014, 44, 2041-2051.	2.7	122
130	Serum Peak Sulfamethoxazole Concentrations Demonstrate Difficulty in Achieving a Target Range: A Retrospective Cohort Study. Current Therapeutic Research, 2014, 76, 104-109.	0.5	16
131	Neurological Abnormalities in Recent-Onset Schizophrenia and Asperger-Syndrome. Frontiers in Psychiatry, 2014, 5, 91.	1.3	16
132	Visual system integrity and cognition in early Huntington's disease. European Journal of Neuroscience, 2014, 40, 2417-2426.	1,2	40
133	Abnormal resting-state connectivity of motor and cognitive networks in early manifest Huntington's disease. Psychological Medicine, 2014, 44, 3341-3356.	2.7	46
134	The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study. Psychological Medicine, 2014, 44, 1867-1878.	2.7	43
135	Source-based morphometry of gray matter volume in patients with schizophrenia who have persistent auditory verbal hallucinations. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 102-109.	2.5	66
136	Cortical Signature of Neurological Soft Signs in Recent Onset Schizophrenia. Brain Topography, 2014, 27, 296-306.	0.8	42
137	Source-based morphometry reveals distinct patterns of aberrant brain volume in delusional infestation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 112-116.	2.5	29
138	Reduced Neural Error Signaling in Left Inferior Prefrontal Cortex in Young Adults With ADHD. Journal of Attention Disorders, 2014, 18, 659-670.	1.5	22
139	Longitudinal task-negative network analyses in preclinical Huntington's disease. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 493-505.	1.8	17
140	Cefpodoxime for Antimicrobial Prophylaxis in Neutropenia: A Retrospective Case Series. Clinical Therapeutics, 2014, 36, 976-981.	1,1	12
141	Clinical significance of frontal cortex abnormalities in Huntington's disease. Experimental Neurology, 2013, 247, 39-44.	2.0	13
142	Abnormal gray and white matter volume in delusional infestation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 19-24.	2.5	73
143	Hippocampal and entorhinal cortex volume decline in cognitively intact elderly. Psychiatry Research - Neuroimaging, 2013, 211, 31-36.	0.9	23
144	Detection of preclinical neural dysfunction from functional connectivity graphs derived from task fMRI. An example from degeneration. Psychiatry Research - Neuroimaging, 2013, 214, 322-330.	0.9	5

#	Article	IF	Citations
145	Neurological Soft Signs and Brainstem Morphology in First-Episode Schizophrenia. Neuropsychobiology, 2013, 68, 91-99.	0.9	36
146	Brain Structure in Preclinical Huntington's Disease: A Multi-Method Approach. Neurodegenerative Diseases, 2013, 12, 13-22.	0.8	21
147	Functional and Structural MRI Biomarkers to Detect Pre-Clinical Neurodegeneration. Current Alzheimer Research, 2013, 10, 125-134.	0.7	16
148	G14â€Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A30.3-A31.	0.9	0
149	Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer's Disease. Current Alzheimer Research, 2012, 9, 507-515.	0.7	27
150	A04â€Default-mode network changes in preclinical Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A1.4-A2.	0.9	0
151	Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 375-391.	1.8	39
152	Orbitofrontal cortex and impulsivity in borderline personality disorder: an MRI study of baseline brain perfusion. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 677-685.	1.8	43
153	Default-mode network changes in preclinical Huntington's disease. Experimental Neurology, 2012, 237, 191-198.	2.0	64
154	Subcortical morphological correlates of impaired clock drawing performance. Neuroscience Letters, 2012, 512, 28-32.	1.0	11
155	Poster #34 ASSESSMENT OF POSITIVE AND NEGATIVE SYMPTOMS USING AN FMRI REWARD-PARADIGM IN A SAMPLE OF HEALTHY SUBJECTS WITH DIFFERENT LEVELS OF SYMPTOM EXPRESSION. Schizophrenia Research, 2012, 136, S103-S104.	1.1	0
156	Magnetic resonance perfusion imaging of auditory verbal hallucinations in patients with schizophrenia. Schizophrenia Research, 2012, 134, 285-287.	1.1	18
157	Reduced Gray to White Matter Tissue Intensity Contrast in Schizophrenia. PLoS ONE, 2012, 7, e37016.	1.1	23
158	Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness. Human Brain Mapping, 2012, 33, 2161-2173.	1.9	49
159	Neurological soft signs and subcortical brain morphology in recent onset schizophrenia. Journal of Psychiatric Research, 2012, 46, 533-539.	1.5	40
160	Catechol-O-Methyl Transferase Modulates Cognition in Late Life: Evidence and Implications for Cognitive Enhancement. CNS and Neurological Disorders - Drug Targets, 2012, 11, 195-208.	0.8	12
161	Quality of life after restorative proctocolectomy and ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: a matter of adjustment. Colorectal Disease, 2011, 13, e358-e365.	0.7	15
162	Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1908-1918.	2.4	54

#	Article	IF	CITATIONS
163	Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease. Experimental Neurology, 2011, 231, 214-222.	2.0	45
164	Dysconnectivity of multiple resting-state networks in patients with schizophrenia who have persistent auditory verbal hallucinations. Journal of Psychiatry and Neuroscience, 2011, 36, 366-374.	1.4	125
165	Aberrant connectivity of resting-state networks in borderline personality disorder. Journal of Psychiatry and Neuroscience, 2011, 36, 402-411.	1.4	98
166	Mechanisms and Applications of Theta-burst rTMS on the Human Motor Cortex. Brain Topography, 2010, 22, 294-306.	0.8	202
167	Functional brain network abnormalities during verbal working memory performance in adolescents and young adults with dyslexia. Neuropsychologia, 2010, 48, 309-318.	0.7	45
168	A Neural Signature of Anorexia Nervosa in the Ventral Striatal Reward System. American Journal of Psychiatry, 2010, 167, 206-212.	4.0	191
169	Cortical Activation during a Pitch Discrimination Task in Tinnitus Patients and Controls – An fMRI Study. Audiology and Neuro-Otology, 2010, 15, 137-148.	0.6	17
170	Increasing Contextual Demand Modulates Anterior and Lateral Prefrontal Brain Regions Associated with Proactive Interference. International Journal of Neuroscience, 2010, 120, 40-50.	0.8	12
171	Can We Prevent Fatal Liver Failure under Valproate?. Pharmacopsychiatry, 2010, 43, 198-200.	1.7	3
172	The value of neuronavigated rTMS for the treatment of depression. Neurophysiologie Clinique, 2010, 40, 37-43.	1.0	64
173	Delusional infestation: Neural correlates and antipsychotic therapy investigated by multimodal neuroimaging. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1215-1222.	2.5	47
174	Pregabalin in the Treatment of Schizophrenic Anxiety. Pharmacopsychiatry, 2009, 42, 124-125.	1.7	19
175	Aberrant functional connectivity of dorsolateral prefrontal and cingulate networks in patients with major depression during working memory processing. Psychological Medicine, 2009, 39, 977-987.	2.7	147
176	Cortical dysfunction in patients with Huntington's disease during working memory performance. Human Brain Mapping, 2009, 30, 327-339.	1.9	72
177	Regional brain activation changes and abnormal functional connectivity of the ventrolateral prefrontal cortex during working memory processing in adults with attentionâ€deficit/hyperactivity disorder. Human Brain Mapping, 2009, 30, 2252-2266.	1.9	142
178	Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience, 2009, 164, 205-219.	1.1	64
179	Temporally anticorrelated brain networks during working memory performance reveal aberrant prefrontal and hippocampal connectivity in patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1464-1473.	2.5	89
180	Neural Hyporesponsiveness and Hyperresponsiveness During Immediate and Delayed Reward Processing in Adult Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2009, 65, 7-14.	0.7	249

#	Article	IF	Citations
181	Altered frontostriatal coupling in preâ€manifest Huntington's disease: effects of increasing cognitive load. European Journal of Neurology, 2008, 15, 1180-1190.	1.7	68
182	Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: A voxel-based morphometry study. Journal of Affective Disorders, 2008, 109, 107-116.	2.0	197
183	Neural correlates of working memory performance in adolescents and young adults with dyslexia. Neuropsychologia, 2008, 46, 640-648.	0.7	45
184	Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington's disease. Experimental Neurology, 2008, 213, 137-144.	2.0	104
185	Volumetric abnormalities associated with cognitive deficits in patients with schizophrenia. European Psychiatry, 2008, 23, 541-548.	0.1	76
186	Respiratory Dysfunction in Sleep Apnea Associated with Quetiapine. Pharmacopsychiatry, 2008, 41, 119-121.	1.7	23
187	ArbeitsgedÃ e htnis — Psychologie. , 2008, , 231-241.		0
188	Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain, 2007, 130, 2845-2857.	3.7	131
189	Valvular Strands and Ischemic Stroke. European Neurology, 2007, 57, 227-231.	0.6	15
190	Working memory dysfunction in schizophrenia compared to healthy controls and patients with depression: Evidence from event-related fMRI. Neurolmage, 2007, 35, 1551-1561.	2.1	87
191	Changes over time in frontotemporal activation during a working memory task in patients with schizophrenia. Schizophrenia Research, 2007, 91, 141-150.	1.1	27
192	Increased left prefrontal activation in patients with unipolar depression: An event-related, parametric, performance-controlled fMRI study. Journal of Affective Disorders, 2007, 101, 175-185.	2.0	115
193	Depressive Symptoms as First Manifestation of Posterior Cortical Atrophy. American Journal of Psychiatry, 2006, 163, 939-940.	4.0	10
194	Differential activation of ventrolateral prefrontal cortex during working memory retrieval. Neuropsychologia, 2006, 44, 2558-2563.	0.7	52
195	Bupropion Augmentation in the Treatment of Chronic Fatigue Syndrome with Coexistent Major Depression Episode. Pharmacopsychiatry, 2006, 39, 152-154.	1.7	22
196	Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. American Journal of Kidney Diseases, 2005, 45, 102-111.	2.1	34
197	Evaluation of a novel event-related parametric fMRI paradigm investigating prefrontal function. Psychiatry Research - Neuroimaging, 2005, 140, 73-83.	0.9	35